Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „concomitant“
Suchtreffer
Begriffe & Kennungen
Abilify Maintena · 4.5 · 29 Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to
Eintrag öffnenAbilify Maintena · 4.5 · Carbamazepine and other CYP3A4 inducers Following concomitant administration of carbamazepine, a strong induce
Eintrag öffnenAbilify Maintena · 4.5 · If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electr
Eintrag öffnenAbilify Maintena · 4.5 · If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electr
Eintrag öffnenAblymico · 4.5 · 6 The small delay of gastric emptying with liraglutide may influence absorption of concomitantly administered
Eintrag öffnenAbrysvo · 4.5 · Abrysvo can be administered concomitantly with: • seasonal influenza vaccines, either standard dose adjuvanted
Eintrag öffnenAclasta · 4.5 · In patients with renal impairment, the systemic exposure to concomitant medicinal products that are primarily
Eintrag öffnenActos · 4.5 · 6 increased when rifampicin is concomitantly administered. Close monitoring of glycaemic control should be con
Eintrag öffnenAdempas · 4.5 · 8 Concomitant use with strong multi pathway CYP and P-gp/BCRP inhibitors The concomitant use of riociguat with
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP1A1, UGT1A1 and UGT1A9 inhibitors From the recombinant CYP isoforms investigated in vi
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP1A1, UGT1A1 and UGT1A9 inhibitors From the recombinant CYP isoforms investigated in vi
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP3A4 inducers Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP3A4 inducers Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease
Eintrag öffnenAdempas · 4.5 · Concomitant use with medicinal products increasing gastric pH Riociguat exhibits a reduced solubility at neutr
Eintrag öffnenAdempas · 4.5 · Concomitant use with medicinal products increasing gastric pH Riociguat exhibits a reduced solubility at neutr
Eintrag öffnenAdempas · 4.5 · Concomitant use with other CYP and P-gp/BCRP inhibitors Medicinal products strongly inhibiting P-gp/BCRP such
Eintrag öffnenAdempas · 4.5 · Concomitant use with other CYP and P-gp/BCRP inhibitors Medicinal products strongly inhibiting P-gp/BCRP such
Eintrag öffnenAdempas · 4.5 · Concomitant use with strong multi pathway CYP and P-gp/BCRP inhibitors The concomitant use of riociguat with s
Eintrag öffnenAdempas · 4.5 · Soluble guanylate cyclase stimulators Concomitant use of riociguat with other soluble guanylate cyclase stimul
Eintrag öffnenAdempas · 4.5 · Soluble guanylate cyclase stimulators Concomitant use of riociguat with other soluble guanylate cyclase stimul
Eintrag öffnen